Clinical trial design issues in mild to moderate Alzheimer disease

David S. Knopman

doi:10.1097/WNN.0b013e318190cf75

Clinical trial design issues in mild to moderate Alzheimer disease

David S. Knopman

Neurology

Research output: Contribution to journal › Review article › peer-review

25 Scopus citations

Abstract

The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old. Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.

Original language	English (US)
Pages (from-to)	197-201
Number of pages	5
Journal	Cognitive and Behavioral Neurology
Volume	21
Issue number	4
DOIs	https://doi.org/10.1097/WNN.0b013e318190cf75
State	Published - Dec 2008

Keywords

Alzheimer disease
Cholinesterase inhibitors
Clinical trials

ASJC Scopus subject areas

Neuropsychology and Physiological Psychology
Cognitive Neuroscience
Psychiatry and Mental health

Access to Document

10.1097/WNN.0b013e318190cf75

Cite this

@article{a48d3b0808324f2eae2a749f1888b763,

title = "Clinical trial design issues in mild to moderate Alzheimer disease",

abstract = "The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old. Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.",

keywords = "Alzheimer disease, Cholinesterase inhibitors, Clinical trials",

author = "Knopman, {David S.}",

year = "2008",

month = dec,

doi = "10.1097/WNN.0b013e318190cf75",

language = "English (US)",

volume = "21",

pages = "197--201",

journal = "Cognitive and Behavioral Neurology",

issn = "1543-3633",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Clinical trial design issues in mild to moderate Alzheimer disease

AU - Knopman, David S.

PY - 2008/12

Y1 - 2008/12

N2 - The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old. Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.

AB - The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old. Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.

KW - Alzheimer disease

KW - Cholinesterase inhibitors

KW - Clinical trials

UR - http://www.scopus.com/inward/record.url?scp=61549102206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549102206&partnerID=8YFLogxK

U2 - 10.1097/WNN.0b013e318190cf75

DO - 10.1097/WNN.0b013e318190cf75

M3 - Review article

C2 - 19057167

AN - SCOPUS:61549102206

SN - 1543-3633

VL - 21

SP - 197

EP - 201

JO - Cognitive and Behavioral Neurology

JF - Cognitive and Behavioral Neurology

IS - 4

ER -

Clinical trial design issues in mild to moderate Alzheimer disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this